Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Ku

Showing results (41-50 of 392) with videos related to

Pageof 40
Sort By:
Surgical Oncology Clinics of North America|June 9, 2009
Role of neoadjuvant therapy for esophageal adenocarcinomaGeoffrey Y Ku, David H Ilson
Seminars in Radiation Oncology|December 5, 2012
Chemotherapeutic options for gastroesophageal junction tumorsGeoffrey Y Ku, David H Ilson
Expert Opinion on Emerging Drugs|June 4, 2013
Emerging tyrosine kinase inhibitors for esophageal cancerGeoffrey Y Ku, David H Ilson
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 15, 1998
[Experimental study on TNF-alpha linked percutaneous isolated hepatic chemoperfusion (PIHP)]N Kusunoki, Y Ku, Y Kuroda
The Kobe Journal of Medical Sciences|August 1, 1992
Serum bile acid monitoring as an early indicator of allograft function in canine orthotopic liver transplantationS Fujiwara, Y Ku, Y Saitoh
Clinical Advances in Hematology & Oncology : H&O|June 3, 2008
Preoperative therapy in esophageal cancerGeoffrey Y Ku, David H Ilson
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 1, 1994
[Comparison of transarterial and transportal heating bypass in canine regional liver hyperthermia]T Nishida, Y Ku, Y Saitoh
Nihon Geka Gakkai Zasshi|March 1, 1994
[Serum beta-N-acetyl hexosaminidase as a new marker of graft viability in canine orthotopic liver transplantation]M Tominaga, Y Ku, Y Kuroda
Chinese Clinical Oncology|November 14, 2017
Systemic therapy for esophagogastric cancer: targeted therapiesTomas G Lyons, Geoffrey Y Ku
Chinese Clinical Oncology|November 14, 2017
Systemic therapy for esophagogastric cancer: immune checkpoint inhibitionTomas G Lyons, Geoffrey Y Ku
Pageof 40

Showing results (41-50 of 392) with videos related to

Sort By:
Pageof 40
Surgical Oncology Clinics of North America|June 9, 2009
Role of neoadjuvant therapy for esophageal adenocarcinomaGeoffrey Y Ku, David H Ilson
Seminars in Radiation Oncology|December 5, 2012
Chemotherapeutic options for gastroesophageal junction tumorsGeoffrey Y Ku, David H Ilson
Expert Opinion on Emerging Drugs|June 4, 2013
Emerging tyrosine kinase inhibitors for esophageal cancerGeoffrey Y Ku, David H Ilson
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 15, 1998
[Experimental study on TNF-alpha linked percutaneous isolated hepatic chemoperfusion (PIHP)]N Kusunoki, Y Ku, Y Kuroda
The Kobe Journal of Medical Sciences|August 1, 1992
Serum bile acid monitoring as an early indicator of allograft function in canine orthotopic liver transplantationS Fujiwara, Y Ku, Y Saitoh
Clinical Advances in Hematology & Oncology : H&O|June 3, 2008
Preoperative therapy in esophageal cancerGeoffrey Y Ku, David H Ilson
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 1, 1994
[Comparison of transarterial and transportal heating bypass in canine regional liver hyperthermia]T Nishida, Y Ku, Y Saitoh
Nihon Geka Gakkai Zasshi|March 1, 1994
[Serum beta-N-acetyl hexosaminidase as a new marker of graft viability in canine orthotopic liver transplantation]M Tominaga, Y Ku, Y Kuroda
Chinese Clinical Oncology|November 14, 2017
Systemic therapy for esophagogastric cancer: targeted therapiesTomas G Lyons, Geoffrey Y Ku
Chinese Clinical Oncology|November 14, 2017
Systemic therapy for esophagogastric cancer: immune checkpoint inhibitionTomas G Lyons, Geoffrey Y Ku
Pageof 40